Evidence map›Paper›PMID 32380316›Full record

ReviewAutoimmunity reviews2020

Convalescent plasma in Covid-19: Possible mechanisms of action.

Manuel Rojas, Yhojan Rodríguez, Diana M Monsalve, Yeny Acosta-Ampudia, Bernardo Camacho, Juan Esteban Gallo, Adriana Rojas-Villarraga, Carolina Ramírez-Santana, Juan C Díaz-Coronado, Rubén Manrique and 3 more

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Autoimmunity reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04468009 (Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma), which is not on this map. Cited by 269 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
269citing papers in PubMed, 10 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04468009 phase2completednot on this map

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

TypeinterventionalSponsorHospital de Infecciosas Francisco Javier MunizRan2020 to 2021Enrolled134ConditionsSARS-Associated Coronavirus, Covid19, SARS-CoV InfectionArmsConvalescent plasma
3 · Its place in the literature

Who cites it

269 citing papers in PubMed, 10 syntheses or guidelines pooled it, 512 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - A case series.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

209 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Manuel RojasCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
Yhojan RodríguezCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia.
Diana M MonsalveCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
Yeny Acosta-AmpudiaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
Bernardo CamachoInstituto Distrital de Ciencia Biotecnología e Investigación en Salud, IDCBIS, Bogota, Colombia.
Juan Esteban GalloGenoma CES, Universidad CES, Medellin, Colombia.
Adriana Rojas-VillarragaFundación Universitaria de Ciencias de la Salud (FUCS), Bogota, Colombia.
Carolina Ramírez-SantanaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
Juan C Díaz-CoronadoInternal Medicine Department, Universidad CES, Medellin, Colombia.
Rubén ManriqueEpidemiology and Biostatistics Research Group, Universidad CES, Medellin, Colombia.
Ruben D MantillaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia.
Yehuda ShoenfeldZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel-Aviv University, Tel Aviv, Israel; Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation.
Juan-Manuel AnayaCenter for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia; Clínica del Occidente, Bogota, Colombia. Electronic address: juan.anaya@urosario.edu.co.
Universidad del Rosario · COClínica CES · COFundación Universitaria de Ciencias de la Salud · COSt Petersburg University · RUUniversidad Autónoma de Occidente · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.

Indexed as

Antibodies, NeutralizingBetacoronavirusClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveLymphocytesPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Antibodies, NeutralizingACE-2 receptorConvalescent plasmaCoronavirusCOVID-19CytokinesIntravenous immunoglobulinsNeutralizing antibodiesSARS-Cov-2

Identifiers

PMID32380316
PMCPMC7198427
OpenAlexW3021816206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.